Clinical trials: Immunotherapy
Alzheimer Disease
A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease
The purpose of this study is to assess whether JNJ-64042056 affects the spread and build up of tau (a protein in brain) when compared with placebo, using brain scan (tau PET) to determine results from specific areas of the brain.
- Trial name
- Reτain (NCT06544616)
- Testing
- JNJ-64042056
- Where
- 90 sites in United States, Australia and 7 more
- Volunteers
- 55 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Lung Neoplasms, Neoadjuvant Therapy
MRD-Guided Postoperative Surveillance and Adaptive Treatment for Resectable Lung Cancer
This study is a prospective single-arm clinical trial targeting patients with stage IB-IIIA non-small cell lung cancer (NSCLC) who have received neoadjuvant immunotherapy.
- Conditions
- Lung Neoplasms, Neoadjuvant Therapy, Immunotherapy, Minimal Residual Disease
- Trial name
- NCT07894458
- Testing
- Adaptive therapy of de-escalation and escalation based on MRD testing and pathological response
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
Gastric Adenocarcinoma
A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric Cancer
The goal of this clinical trial is to learn if the combination of disitamab vedotin, tunlametinib, and a PD-1 antibody works to treat HER2-overexpressing advanced gastric cancer in patients who have already received at least two…
- Trial name
- DTP-HER2 (NCT07507526)
- Testing
- Tunlametinib+PD-1 mAb
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Sun Yat-sen University
Multiple Myeloma
A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation
The purpose of this study is to test any good and bad effects of giving a combination of study drugs before and after autologous stem cell transplant.
- Trial name
- NCT03556332
- Testing
- Carfilzomib, Lenalidomide, Dexamethasone
- Where
- 12 sites in United States
- Volunteers
- 41 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
A Study of STM-416p Administered Intraoperatively to Patients Undergoing Radical Prostatectomy
- Trial name
- NCT06450106
- Testing
- STM-416p
- Where
- 4 sites in United States, Australia
- Volunteers
- 18 people
- Sponsor
- SURGE Therapeutics
Hepatocellular Carcinoma (HCC)
Irreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma
Advanced hepatocellular carcinoma (HCC) remains a major therapeutic challenge. Although targeted therapy combined with immune checkpoint inhibitors has improved clinical outcomes, the objective response rate and conversion…
- Trial name
- NCT07832006
- Testing
- Irreversible Electroporation, Lenvatinib, Sintilimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shunda Du
Metastatic Castration Resistant Prostate Cancer
PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr)
This investigator driven study will examine the safety, tolerability and efficacy of the combination of 177Lutetium-PSMA (177Lu-PSMA) and pembrolizumab in patients with metastatic Castration Resistant Prostate Cancer (mCRPC).
- Trial name
- PRINCE (NCT03658447)
- Testing
- Pembrolizumab, 177Lu-PSMA
- Where
- 4 sites in Australia
- Volunteers
- 37 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Melanoma Stage III, Melanoma Stage IV
A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic Melanoma
The purpose of this study is to determine if TBI-1401(HF10) in combination with ipilimumab is effective in Japanese patients with stages IIIB, IIIC, or IV unresectable or metastatic melanoma.
- Trial name
- NCT03153085
- Testing
- TBI-1401(HF10), Ipilimumab
- Where
- 12 sites in Japan
- Volunteers
- 28 people
- Sponsor
- Takara Bio Inc.
Advanced Renal Cell Carcinoma
Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial
This study is a randomized, open label, multicenter Phase II trial to evaluate the efficacy and safety of botensilimab (a novel Fc enhanced Tree depleting anti-CTLA4) and balstilimab (a novel anti-PD1) relative to ipilimumab and…
- Trial name
- ARCITECT (NCT05928806)
- Testing
- Botensilimab, Balstilimab, Ipilimumab
- Where
- 13 sites in United States
- Volunteers
- 120 people
- Sponsor
- Michael B. Atkins, MD
Non-small Cell Lung Cancer
Split-course Hypofractionated Radiotherapy With Concurrent Chemotherapy in Locally Advanced Non-small Cell Lung Cancer
This Phase II study is to determine the efficacy of split-course thoracic radiotherapy plus concurrent chemotherapy with or without consolidation immunotherapy for patients with local advanced non-small cell lung cancer.
- Trial name
- NCT04212052
- Testing
- split-course radiotherapy, concurrent chemotherapy, consolidation immunotherapy
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Sun Yat-sen University
Allergic Rhinitis Due to Grass Pollen
Intralymphatic Immunotherapy Enhanced by Vitamin-D, a Randomized Placebo-controlled Trial and Comparison With SLIT
A national, multicenter, randmised double blind study with parallell arms. 360 patients with grass induced allergic rhinitis will be open randomised 1:2 to 3 years Grazax sublingual immunotherapy or 3 intralymphatic injections…
- Trial name
- ILIT vs SLIT (NCT06061848)
- Testing
- SLIT Grazax ALK Nordic 75 000 SQ-T, ILIT + Vitamin D
- Where
- 3 sites in Sweden
- Volunteers
- 360 people
- Sponsor
- Lars Olaf Cardell
Microsatellite Stable (MSS) Colorectal Cancer (CRC), Metastatic Colorectal Cancer (CRC)
Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer
The goal of this study is to learn if a new combination treatment is effective for patients with microsatellite stable, advanced colorectal cancer. The study treatment combines 3 drugs: atezolizumab, bevacizumab, and tiragolumab.
- Conditions
- Microsatellite Stable (MSS) Colorectal Cancer (CRC), Metastatic Colorectal Cancer (CRC), Colorectal Cancer Stage IV
- Trial name
- NCT06784947
- Testing
- Pre-Treatment Biopsy, On-Treatment Biopsy, Tiragolumab
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Colorado, Denver
Melanoma, Melanoma (Skin)
Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma Patients
In the BRIM-3 trial, which was conducted in patients with previously untreated advanced melanoma harboring the BRAF V600E mutation, vemurafenib, a potent inhibitor of mutated BRAF, was associated with prolonged overall survival…
- Conditions
- Melanoma, Melanoma (Skin), Melanoma Stage
- Trial name
- VECODUE (NCT03224208)
- Testing
- Vemurafenib, Cobimetinib
- Where
- Italy
- Volunteers
- 9 people
- Sponsor
- Fondazione Melanoma Onlus
Stomach Cancer, Gastro Esophageal Junction Cancer
Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)
In this explorative study, patients with resectabel cancer of the stomach or stomach-oesophagealjunction cancer will receive neoadjuvant treatment.
- Trial name
- PANDA (NCT03448835)
- Testing
- Atezolizumab, Capecitabine, Oxaliplatin
- Where
- 2 sites in Netherlands
- Volunteers
- 20 people
- Sponsor
- The Netherlands Cancer Institute
Endometriosis
Does Immunotherapy Have a Role in the Management of Endometriosis?
Pathological specimens of 40 women that had been operated for endometriosis will be included in this study. These tissues will be stained with a marker named as PDL-1 in pathological examination.
- Trial name
- NCT03464799
- Testing
- immunohistochemical staining
- Volunteers
- 40 people
- Sponsor
- Kanuni Sultan Suleyman Training and Research Hospital
Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, Relapsed, Adult
Natural Killer-cell Therapy for Acute Myeloid Leukemia
This study investigates an innovative treatment for relapsed or refractory acute myeloid leukemia exploiting administration of ex vivo-generated allogeneic natural killer (NK) cells with preceding non-myeloablative conditioning…
- Trial name
- NK4AML (NCT04347616)
- Testing
- UCB-NK cells, IL-2
- Where
- Netherlands
- Volunteers
- 9 people
- Sponsor
- Radboud University Medical Center
Non-small Cell Lung Cancer
Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung Cancer
The majority of patients diagnosed with advanced NSCLC are treated with platinum-doublet chemotherapy regimens, except those harboring specific oncogenic drivers such as epidermal growth-factor-receptor (EGFR) mutations or…
- Trial name
- VinMetAtezo (NCT03801304)
- Testing
- Atezolizumab, Vinorelbine
- Where
- 13 sites in France
- Volunteers
- 80 people
- Sponsor
- University Hospital, Brest
Hepatocellular Carcinoma (HCC)
TACE and/or HAIC Combined With Molecular-targeted Therapy and Immunotherapy for HCC
The safety, clinical efficacy and prognostic factors of transcatheter arterial chemoembolization (TACE) and/or hepatic artery infusion chemotherapy (HAIC) combined with targeted immunotherapy for primary hepatocellular carcinoma…
- Trial name
- NCT07658833
- Testing
- TACE (transarterial chemoembolization) combined with targeted/immunotherapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Endometrial Cancer
From Fetal-maternal Interface Immune Tolerance to Endometrial Cancer Immune Escape: Potential Targets for Immunotherapy
Non-interventional retro-prospective study on Endometrial tissue samples taken from surgically treated patients.
- Trial name
- NCT06273878
- Where
- 2 sites in Italy
- Volunteers
- 80 people
- Sponsor
- Regina Elena Cancer Institute
Lung Cancer, Non-Small Cell
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
This study will monitor the safety of novel immunotherapy combinations in participants with Programmed death ligand-1 (PD L-1) high (Tumor cells [TC]/ Tumor proportion score [TPS] >= 50%), previously untreated, unresectable…
- Trial name
- NCT05565378
- Testing
- Pembrolizumab, Dostarlimab, Belrestotug
- Where
- 99 sites in United States, Argentina and 20 more
- Volunteers
- 351 people
- Sponsor
- GlaxoSmithKline